PhilipJMeaseMD

Director, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and Clinical Professor University of Washington School of Medicine

Join to view full profile

Dr. Mease is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mease's full profile

Already have an account?

Office
1101 Madison St
Ste 1000
Seattle, WA 98104
Phone+1 206-386-2001

Fax+1 206-386-2083

Education & Training

University of WashingtonFellowship, Rheumatology, 1981 - 1982
University of WashingtonResidency, Internal Medicine, 1977 - 1981
Stanford University School of MedicineClass of 1977

Certifications & Licensure

WA State Medical License 1978 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

LIfetime Achievement Award National Psoriasis Foundation, 2019
America's Top Doctors Castle Connolly, 2008-2014
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rituxan With or Without Methotrexate in Psoriatic Arthritis Start of enrollment: 2006 Dec 01
Completed
Phase 1
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 Start of enrollment: 2014 Jul 01
Terminated
Not Applicable
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Start of enrollment: 2015 Sep 14
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives.
Philip J Mease, M Elaine Husni, Evan Siegel, Daniel E Furst, Melissa Mcilraith
ACR Open Rheumatology. 2025-01-01
The 1st GRAPPA International Meeting on Psoriasis and Psoriatic Arthritis - 1º Encontro Internacional do GRAPPA Sobre Psoríase e Artrite Psoriásica.
Claudia Goldenstein-Schainberg, Dimitri Luz Felipe da Silva, Enrique R Soriano, Laura J Savage, Philip J Mease
The Journal of Rheumatology. 2025-01-01
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.
Victoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, Marina Magrey, Helena Marzo-Ortega
The Journal of Rheumatology. 2025-01-01

Journal Articles

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
Alice Gottlieb, Philip Mease, Arthritis Care & Research
Dual Inhibition of Tumour Necrosis Factor and Interleukin-17A with ABT-122: Open-Label Long-Term Extension Studies in Rheumatoid Arthritis or Psoriatic Arthritis
Philip Mease, MD, Rheumatology
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Philip Mease, MD, Arthritis Care & Research
Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis over 2 Years: Results from the FUTURE 2 Study
Philip J Mease, Vibeke Strand, BioMed Central
Phase 2 Study of ABT‐122, a TNF‐ and IL‐17A–Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis with Inadequate Methotrexate Response
Philip Mease, MD, Arthritis & Rheumatology
Join now to see all

Lectures

24-Week Results From the RAPID-PsA Study
Annual European Congress of Rheumatology 2012, Berlin, Germany
24-Week Results From the RAPID-PsA Study
European League Against Rheumatism, Annual European Congress of Rheumatology 2012, Berlin, Germany

Authored Content

Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020

Press Mentions

Guselkumab Provides Long-Term Relief in Psoriatic ArthritisOctober 22nd, 2024
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (Bimekizumab) Versus SKYRIZI® (Risankizumab) in Active Psoriatic ArthritisSeptember 30th, 2024
Managing Obesity & Fibromyalgia in Psoriatic DiseaseSeptember 9th, 2024
Join now to see all